Quick answer. In Argentina, medical devices are registered with ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica); devices are classed I–IV by risk; a CE-marked or otherwise reference-approved Class I or II device is the classic candidate for the simplified registration by Declaración Jurada (DDJJ / sworn declaration), filed electronically through ANMAT's HELENA platform, while Classes III and IV require a full technical-dossier evaluation; the registration must be held by a locally authorized representative/importer with a designated Technical Director — which bioaccess® provides, holding the registration in the manufacturer's name.
The current framework (Disposición ANMAT N° 64/2025, which replaced 2318/2002) keeps four risk classes — Class I low risk, Class II low-moderate, Class III moderate-high, Class IV high; the definitive class comes from a short review of the technical file before filing and sets the pathway and dossier depth.
Class I/II via DDJJ is comparatively quick; Class III/IV runs several months during ANMAT's technical review; Argentine government fees are modest relative to the region (indicative only — agency timelines vary and are outside our control).
Since Disposición ANMAT 4446/2025 (effective August 2025), imports of Class I and II registered devices are handled by a 48-hour post-nationalization import notice (a sworn statement, free of charge) rather than a prior per-shipment authorization — a meaningful simplification for commercial supply.
No — it must be held by a locally authorized establishment. bioaccess® serves as your Registration Holder (Titular), Legal Representative, and Importer of Record, holding it for your benefit so you can appoint and rotate distributors freely.
No, but it supports it and, for Class I/II, opens the simplified DDJJ route; eligibility rests on ANMAT's classification, confirmed before filing.
ANMAT treating the device as higher-risk by its invasiveness, energy delivered, or intended use; we confirm the class in the review that opens the engagement.
Book a 30-min Argentina market-access call · Medical device registration in Latin America: 2026 country-by-country guide
General information as of 2026; ANMAT requirements change and the definitive pathway is confirmed at scoping. bioaccess® provides regulatory representation, not legal advice.